James Parsons
Directeur/Membre du Conseil chez DIAMEDICA THERAPEUTICS INC.
Fortune : 294 199 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Matthew Coffey | M | - | 13 ans | |
Rick Pauls | M | 52 | 19 ans | |
Deborah Brown | F | - | 7 ans | |
Scott Kellen | M | 59 | 6 ans | |
Wayne Pisano | M | 69 | 11 ans | |
Andrew Muratore | M | - | 3 ans | |
Deborah Baron | F | 55 | 3 ans | |
Brett Whalen | M | - | 1 ans | |
Kirk Look | M | - | 21 ans | |
David Wambeke | M | - | 1 ans | |
Cynthia Pussinen | F | - | 1 ans | |
Frank Shannon | M | - | 3 ans | |
Richard Pilnik | M | 67 | 15 ans | |
Charles Semba | M | 64 | 3 ans | |
Julie VanOrsdel Daves | F | - | - | |
Angela Holtham | F | 73 | 10 ans | |
Michael Giuffre | M | 68 | 14 ans | |
Bernd Seizinger | M | 67 | 9 ans | |
Tanya Lewis | F | 53 | 1 ans | |
Paul Papi | M | - | 8 ans | |
Steven Sangha | M | - | 1 ans | |
Delfina Siroen | F | - | - | |
Dominic Cundari | M | - | 2 ans | |
Modestus Obochi | M | - | 1 ans | |
Richard Kuntz | M | 66 | 1 ans | |
Thomas Heineman | M | - | 4 ans | |
Kathleen Large | F | 64 | 5 ans | |
Jonathan Rigby | M | 56 | 2 ans | |
Lorianne K. Masuoka | M | 62 | - | |
Jon Patton | M | - | 4 ans | |
Christopher Barnes | M | - | - | |
Daniel Mahony | M | - | 2 ans | |
Patricia Andrews | F | 66 | - | |
Ambarish Shah | M | - | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
David Allan | M | 82 | 7 ans | |
Philip Toleikis | M | - | 15 ans | |
Robert Gundel | M | - | 5 ans | |
Niclas Stiernholm | M | - | 8 ans | |
Robert A. Uger | M | 53 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 8 ans |
Michael G. Moore | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 16 ans |
Robert L. Kirkman | M | 75 | 8 ans | |
Calvin Stiller | M | 83 | 8 ans | |
Philippe Couillard | M | 67 | 3 ans | |
Frank Holler | M | 67 | 9 ans | |
Jan Skvarka | M | 57 | 2 ans | |
George Adams | M | 76 | 5 ans | |
Todd A. Verdoorn | M | 63 | 3 ans | |
Helena Tayton-Martin | M | 57 | 4 ans | |
Zhen Yu Xiao | M | 50 | - | |
Dawson J. Reimer | M | 53 | 5 ans | |
Luke Beshar | M | 65 | 7 ans | |
Rodney D. Gloss | M | 67 | 6 ans | |
Paul Walker | M | 49 | 1 ans | |
Aziz Mekouar | M | - | - | |
Mark Robbins | M | - | 3 ans | |
R. Dean Peterson | M | - | 4 ans | |
Penka Petrova | M | 56 | 8 ans | |
Scott Myers | M | 57 | - | |
Scott Duncan | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
Bruce A. Weber | M | - | 7 ans | |
Janet Clennett | F | - | - | |
Mickey M. Yaksich | M | - | - | |
Graham Strachan | M | 85 | 5 ans | |
Raafat E. F. Fahim | M | 70 | 1 ans | |
Rosemary Harrison | M | 41 | 1 ans | |
Thomas Reynolds | M | 65 | 7 ans | |
Jeffrey Bacha | M | 56 | 14 ans | |
Paolo Pucci | M | 63 | 1 ans | |
Michael Kamarck | M | 73 | 1 ans | |
Mohammad Azab | M | 68 | 2 ans | |
Michael R. Sonnenreich | M | 85 | 6 ans | |
Walter P. von Wartburg | M | 84 | 4 ans | |
James DeMesa | M | 66 | 9 ans | |
Leonard Kruimer | M | 66 | 3 ans | |
Amy Burroughs | F | 54 | 2 ans | |
Hans P. Black | M | 71 | 8 ans | |
Bill Lambert | M | 72 | 4 ans | |
Mark Williams | M | 52 | 11 ans | |
Ingmar Bruns | M | 49 | 1 ans | |
John Savage | M | - | - | |
Yaping Shou | M | - | 2 ans | |
Abdelmalik Slassi | M | 62 | 3 ans | |
Jennifer Hamilton | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
Alan A. Steigrod | M | 86 | - | |
Lihor A. Simkevitz | F | - | 1 ans | |
Beverly Incledon | M | - | - | |
Albert Agro | M | 59 | - | |
Craig Binnie | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
Michael J. Gresser | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 4 ans |
Hermanth Varghese | M | 49 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
Eric Sievers | M | 60 | 3 ans | |
Geoffrey Collett | M | - | 3 ans | |
Catherine Mackey | M | 68 | - | |
Scott M. Langille | M | 67 | 2 ans | |
Peter Murray | M | - | - | |
Denis Ho | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
Don B. Rix | M | 93 | - | |
John Dietrich | M | 77 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 6 ans |
Benjamin Looker | M | 42 | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 79 | 79,80% |
Etats-Unis | 21 | 21,21% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- James Parsons
- Réseau Personnel